Familial Renal Cancer: Molecular Genetics and Surgical Management

Department of Urology, National Naval Medical Center, Bethesda, MD 20889, USA.
International journal of surgical oncology 08/2011; 2011:658767. DOI: 10.1155/2011/658767
Source: PubMed

ABSTRACT Familial renal cancer (FRC) is a heterogeneous disorder comprised of a variety of subtypes. Each subtype is known to have unique histologic features, genetic alterations, and response to therapy. Through the study of families affected by hereditary forms of kidney cancer, insights into the genetic basis of this disease have been identified. This has resulted in the elucidation of a number of kidney cancer gene pathways. Study of these pathways has led to the development of novel targeted molecular treatments for patients affected by systemic disease. As a result, the treatments for families affected by von Hippel-Lindau (VHL), hereditary papillary renal carcinoma (HPRC), hereditary leiomyomatosis renal cell carcinoma (HLRCC), and Birt-Hogg-Dubé (BHD) are rapidly changing. We review the genetics and contemporary surgical management of familial forms of kidney cancer.

  • Seminars in Diagnostic Pathology 11/2013; 30(4):263-83. DOI:10.1053/j.semdp.2013.11.009 · 1.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The heterogeneity of renal cell carcinoma (RCC) poses a challenge for designing clinically applicable diagnostic and screening investigations, predictive and prognostic biomarkers, and targeted molecular therapies. Hereditary RCC syndromes harbor specific driver gene mutations, and their discoveries have provided unequivocal insight into the pathogenomic landscape of RCCs. These observed genetic aberrations correspond to a diverse range of dysplastic metabolic processes, including mutations in genes encoding tricarboxylic acid (TCA) cycle enzymes, defects in hypoxic and antioxidant signaling, and abnormalities in nutrient-sensing phosphorylation cascades. Medical management of RCC focused on understanding and correcting these metabolic abnormalities may refine current RCC screening, diagnosis, and treatment. This review describes RCC subtypes associated with TCA and intermediary metabolic defects, outlining salient clinical features, genetic and molecular pathologies, medical management, and dynamic research areas that may affect future practice.Kidney International advance online publication, 3 July 2013; doi:10.1038/ki.2013.245.
    Kidney International 07/2013; 84(4). DOI:10.1038/ki.2013.245 · 8.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As our understanding of the molecular events leading to the development and progression of genitourologic malignancies, new markers of detection, prognostication, and therapy prediction can be exploited in the management of these prevalent tumors. The current review discusses the recent advances in prostate, bladder, renal, and testicular neoplasms that are pertinent to the anatomic pathologist.
    Advances in anatomic pathology 05/2013; 20(3):175-203. DOI:10.1097/PAP.0b013e3182863f80 · 3.10 Impact Factor

Preview (2 Sources)

Available from